MeiraGTx Holdings (MGTX) Change in Accured Expenses (2017 - 2025)
MeiraGTx Holdings' (MGTX) quarterly Change in Accured Expenses came in at $8.7 million in Q4 2025, down 6.95% YoY from $9.4 million in Q4 2024, and up 185.39% on a QoQ basis from -$10.2 million in Q3 2025.
Analysis
MeiraGTx Holdings (MGTX) Change in Accured Expenses (2017 - 2025) Analysis & Trends
MeiraGTx Holdings (MGTX) has 9 years of Change in Accured Expenses data on file, last reported at $8.7 million in Q4 2025.
- Quarterly Change in Accured Expenses fell 6.95% year-over-year to $8.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.4 million (up 131.59% YoY) and the FY2025 annual result came in at $4.4 million, up 131.59% from the prior year.
- Change in Accured Expenses rose to $8.7 million in Q4 2025, from -$10.2 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $13.5 million in Q4 2023 to a low of -$24.2 million in Q1 2024.
- A 5-year average of -$313105.3 and a median of $1.6 million in 2024 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 11956.52% — and 2025, when it tumbled 748.48%.
- Tracing MGTX's Change in Accured Expenses over 5 years: stood at $5.0 million in 2021, then plunged by 51.98% to $2.4 million in 2022, then soared by 460.92% to $13.5 million in 2023, then plunged by 30.62% to $9.4 million in 2024, then dropped by 6.95% to $8.7 million in 2025.
- The last three Change in Accured Expenses figures came in at $8.7 million (Q4 2025), -$10.2 million (Q3 2025), and $9.5 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | MeiraGTx Holdings | 1.27 Bn | 1.13 Bn | 315.67 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 21.99 Mn |
| Sep 30, 2025 | 40.15 Mn |
| Jun 30, 2025 | -9.01 Mn |
| Mar 31, 2025 | -3.59 Mn |
| Dec 31, 2024 | 9.39 Mn |
| Sep 30, 2024 | 1.58 Mn |
| Jun 30, 2024 | -697,000.00 |
| Mar 31, 2024 | -24.23 Mn |
| Dec 31, 2023 | 12.56 Mn |
| Sep 30, 2023 | 3.32 Mn |
| Jun 30, 2023 | -5.77 Mn |
| Mar 31, 2023 | -11.47 Mn |
| Dec 31, 2022 | 11.02 Mn |
| Sep 30, 2022 | 2.65 Mn |
| Jun 30, 2022 | 2.77 Mn |
| Mar 31, 2022 | -3.83 Mn |
| Dec 31, 2021 | 10.13 Mn |
| Sep 30, 2021 | 3.04 Mn |
| Jun 30, 2021 | 23,000.00 |
| Mar 31, 2021 | -5.07 Mn |